Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects

Journal of Infectious Diseases

Volumn 197, Issue 1, 2008, Pages 109-116

  Twigg III, Homer L ^a   Weiden, Michael ^b   Valentine, Fred ^b   Schnizlein Bick, Carol T ^a   Bassett, Roland ^c   Zheng, Lu ^c   Wheat, Joseph ^a   Day, Richard B ^a   Rominger, Helen ^a   Collman, Ronald G ^d   Fox, Lawrence ^e   Brizz, Barbara ^f   Dragavon, Joan ^g   Coombs, Robert W ^g   Bucy, R Pat ^h  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ALVEOLUS CELL; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRONCHOALVEOLAR LAVAGE FLUID; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; PULMONARY ALVEOLI; RNA, VIRAL; VIRAL LOAD;

EID: 39349088338     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/523766     Document Type: Article

References (31)

1. Murray JF, Mills J. Pulmonary infectious complications of human immunodeficiency virus infection. Part II. Am Rev Respir Dis 1990; 141:1582-98.
2. Murray JF, Mills J. Pulmonary infectious complications of human immunodeficiency virus infection. Part I. Am Rev Respir Dis 1990; 141:1356-72.
3. Clarke JR, Robinson DS, Coker RJ, Miller RF, Mitchell DM. AIDS and the lung: update 1995. 4. Role of the human immunodeficiency virus within the lung. Thorax 1995; 50:567-76.
4. Guillon JM, Autran B, Denis M, et al. Human immunodeficiency virusrelated lymphocytic alveolitis. Chest 1988; 94:1264-70.
5. Plata F, Autran B, Martins LP, et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 1987; 328:348-51.
6. Johnson SC, Gerber JG. Advances in HIV/AIDS therapy. Adv Intern Med 2000; 45:1-40.
7. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276:960-4.
8. Twigg HL, Soliman DM, Day RB, et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999; 159:1439-44.
9. Saha BK, Tian B, Bucy RP. Quantitation of HIV-1 by real-time PCR with a unique fluorogenic probe. J Virol Methods 2001; 93:33-42.
10. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18:5294-9.
11. Vet JA, Majithia AR, Marras SA, et al. Multiplex detection of four pathogenic retroviruses using molecular beacons. Proc Natl Acad Sci USA 1999; 96:6394-9.
12. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60:532-8.
13. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990; 141:S169-202.
14. Twigg HL III, Soliman DM, Spain BA. Impaired alveolar macrophage accessory cell function and reduced incidence of lymphocytic alveolitis in HIV-infected patients who smoke. AIDS 1994; 8:611-8.
15. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
16. Grossman Z, Polis M, Feinberg MB, et al. Ongoing HIV dissemination during HAART. Nat Med 1999; 5:1099-104.
17. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 2000; 284:223-8.
18. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-66.
19. Li Q, Schacker T, Carlis J, Beilman G, Nguyen P, Haase AT. Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to antiretroviral therapy. J Infect Dis 2004; 189:572-82.
20. Guadalupe M, Sankaran S, George MD, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80:8236-47.
21. + monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002; 76:707-16.
22. Strain MC, Gunthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003; 100:4819-24.
23. + T cells. Nat Med 2003; 9:727-8.
24. Schaerli P, Moser B. Chemokines: control of primary and memory T-cell traffic. Immunol Res 2005; 31:57-74.
25. Saltini C, Kirby M, Trapnell BC, Tamura N, Crystal RG. Biased accumulation of T lymphocytes with "memory"-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med 1990; 171:1123-40.
26. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336:1531-2.
27. Kirk O, Gatell JM, Mocroft A, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162:865-72.
28. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000; 162:64-7.
29. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416-29.
30. Yearsley MM, Diaz PT, Knoell D, Nuovo GJ. Correlation of HIV-1 detection and histology in AIDS-associated emphysema. Diagn Mol Pathol 2005; 14:48-52.
31. Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132:369-72.